MADRID, Jan 15 (Reuters) - Spanish biotechnology company Zeltia ZEL.MC said on Thursday it was widening Phase II clinical trials on its Aplidin drug after it showed “excellent” results in a study to treat Peripheral T-cell lymphomas.
The study, which treated 17 patients with Aplidin, was presented at the 50th edition of the American Society of Hematology Congress in December.
Aplidin is currently in Phase II trials for solid tumours and haematological malignancies.
It is the second most advanced drug being developed by Zeltia’s PharmaMar unit after Yondelis, which is sold in Europe for the treatment of soft tissue sarcoma.
PharmaMar has also initiated studies on the effect of Aplidin in combination with other anti-cancer drugs ahead of possible Phase III trials.
At 1145 GMT, Zeltia shares gained 5.36 percent to 3.54 euros, outpacing a 3.79 percent gain on Madrid's general index .SMSI. (Reporting by Tomas Gonzalez; Translating by Tracy Rucinski; Editing by Jon Loades-Carter)